Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.89 |
| ▸ | CA4 | P22748 | 3/20 | 0.73 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL9116209 | 1.00 | CA1 (0.89) | CA1CA4FAHD1LMNATSHR | |
| Acetic Acid SCHEMBL9118173 | 1.00 | CA1 (0.89) | CA1CA4FAHD1LMNATSHR | |
| Acetic Acid SCHEMBL9117468 | 1.00 | CA1 (0.89) | CA1CA4FAHD1LMNATSHR | |
| Acetic Acid SCHEMBL9117998 | 1.00 | CA1 (0.89) | CA1CA4FAHD1LMNATSHR | |
| Acetic Acid SCHEMBL1254 | 1.00 | — | — | |
| Acetic Acid SCHEMBL3447879 | 1.00 | CA1 (0.89) | CA1CA4FAHD1LMNATSHR | |
| Acetic Acid SCHEMBL5049841 | 1.00 | CA1 (0.89) | CA1CA4FAHD1LMNATSHR | |
| Acetic Acid SCHEMBL9120233 | 1.00 | CA1 (0.89) | CA1CA4FAHD1LMNATSHR | |
| Acetic Acid SCHEMBL2598301 | 0.95 | CA1 (0.90) | CA1CA4FAHD1LMNATSHR | |
| Acetic Acid SCHEMBL6278277 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1345884-A1 | ANTI-VIRAL COMPOUNDS | Aids Care Pharma Limited (IE) | 2003-09-24 | — | — | EP | claimed |
| WO-2002044121-A1 | ANTI-VIRAL COMPOUNDS | AIDS CARE PHARMA LIMITED (IE) | 2002-06-06 | — | — | WO | claimed |
| EP-1367044-B1 | Calixarene-derivatives having anti-viral activity | AIDS CARE PHARMA LTD (IE) | 2008-11-19 | — | — | EP | disclosed |
| US-7338977-B2 | Anti-viral compounds | AIDS CARE PHARMA LIMITED (IE) | 2008-03-04 | — | — | US | disclosed |
| US-20050113454-A1 | Anti-viral compounds | AIDS CARE PHARMA LIMITED (IE) | 2005-05-26 | — | — | US | disclosed |
| EP-1367044-A1 | Calixarene-derivatives having anti-viral activity | Aids Care Pharma Limited (IE) | 2003-12-03 | — | — | EP | disclosed |
| EP-1345884-A1 | ANTI-VIRAL COMPOUNDS | Aids Care Pharma Limited (IE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002044121-A1 | ANTI-VIRAL COMPOUNDS | AIDS CARE PHARMA LIMITED (IE) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113454-A1 | Anti-viral compounds | RNASEH1, H1-0, SARS1 | CA1 3385/4885CA4 2061/4885FAHD1 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.